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Although elevated levels of C-reactive protein (CRP) independently predict increased risk of development of metabolic syndrome,
diabetes, myocardial infarction, and stroke, comprehensive analysis of the inﬂuence of genetic variation on CRP is not available. To
address this issue, we performed a genome-wide association study among 6345 apparently healthy women in which we evaluated
336,108 SNPs as potential determinants of plasma CRP concentration. Overall, seven loci that associate with plasma CRP at levels
achieving genome-wide statistical signiﬁcance were found (range of p values for lead SNPs within the seven loci: 1.9 3 108 to 6.2 3
1028). Two of these loci (GCKR and HNF1A) are suspected or known to be associated with maturity-onset diabetes of the young, one
is a gene-desert region on 12q23.2, and the remaining four loci are in or near the leptin receptor protein gene, the apolipoprotein E
gene, the interleukin-6 receptor protein gene, or the CRP gene itself. The protein products of six of these seven loci are directly involved
in metabolic syndrome, insulin resistance, beta cell function, weight homeostasis, and/or premature atherothrombosis. Thus, common
variation in several genes involved in metabolic and inﬂammatory regulation have signiﬁcant effects on CRP levels, consistent with
CRP’s identiﬁcation as a useful biomarker of risk for incident vascular disease and diabetes.C-reactive protein (CRP) is a pattern-recognition molecule
of innate immunity recognized 80 years ago as an acute-
phase reactant and a hallmark of low-grade systemic in-
ﬂammation. Plasma concentrations of CRP within the
low-normal range independently predict incident meta-
bolic syndrome, type 2 diabetes, myocardial infarction,
and stroke in otherwise healthy men and women.1–5
Although environmental factors such as obesity, smoking,
and hormone-replacement therapymodify CRP levels, var-
iation in CRP is known to be heritable.6 To date, candidate-
gene studies have largely focused on the CRP gene itself
and explained only a fraction of the estimated variance
due to genetics.7–10 It has thus been hypothesized that sub-
stantive genetic effects on CRP are present outside the CRP
locus and that identiﬁcation of these additional loci might
provide insight into mechanisms underlying relationships
between CRP, insulin resistance, metabolic syndrome, and
vascular events.
To address these issues, we conducted a genome-wide
association study among 6345 apparently healthy women
in the Women’s Genome Health Study (WGHS), in which
we evaluated 336,108 single nucleotide polymorphisms
(SNPs) satisfying our quality criteria as potential determi-
nants of plasma CRP level. Details of the rationale, design,
and methodology of the WGHS are described elsewhere.11
In brief, participants in the WGHS include American
women with no prior history of cardiovascular disease,
cancer, or othermajor chronic illness, who provided a base-
line blood sample during the enrollment phase of the
Women’s Health Study (between 1992 and 1995) and con-
sent for blood-based analyses related to the study of theThe Amrisk of incident chronic diseases. All baseline blood sam-
ples underwent measurement for high-sensitivity C-reac-
tive protein (hsCRP) via a validated immunoturbidometric
method (Denka Seiken, Tokyo, Japan). DNA extracted from
the baseline blood samples underwent SNP genotyping via
the Illumina Inﬁnium II assay for querying of a genome-
wide set of 318,237 SNP markers (Human Hap300 panel).
An additional focused panel of 45,571 SNP markers was
queried as well; these were selected to enhance coverage
of genomic regions without regard to allele frequency, in
which we had a strong a priori interest owing to the pres-
ence of genes believed to be of relevance to metabolic,
cardiovascular, and inﬂammatory diseases or to biologic
function in general. The study protocol was approved by
the institutional review board of the Brigham and
Women’s Hospital (Boston, MA, USA).
Before any genetic analyses were performed, SNPs were
excluded from analysis that had a low call rate (%90 per-
cent), and participants were excluded when genotyping
failed for >2 percent of SNPs. For all SNPs and samples
meeting these criteria, Hardy-Weinberg equilibrium was
evaluated with an exact method12 for identiﬁcation of
potential genotyping errors; SNPs with Hardy-Weinberg p
values< 106 were eliminated from analysis. We also com-
pared the Illumina-based SNP data for each individual par-
ticipant for a panel of 44 SNPs that had previously been
ascertained in this population with alternative genotyping
technologies; this step was used as a secondary check to
ensure accurate specimen labeling prior to any analyses.
In total, 336,108 SNPs with minor allele frequencies > 1
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We limited our evaluation to 6345 nondiabetic partici-
pants in the WGHS who were of European ancestry and
were not taking lipid-lowering agents. A principal-compo-
nent analysis using 1443 ancestry-informative SNPs was
performed in order to conﬁrm self-reported ancestry with
PLINK.12 In brief, these SNPs were had an Fst higher than
0.4 in HapMap populations (YRB, CEU, CHBþJPT) and
had inter-SNP distances of at least 500 kb in order to
minimize linkage disequilibrium. Different ethnic groups
were clearly distinguished with the ﬁrst two principal
components.
Genotyping was performed in two stages, with an initial
group of 4418 study participants (WGHS-1) and then with
a second group of 1927 participants (WGHS-2). In all statis-
tical analyses, we adjusted plasma levels of CRP on an a pri-
ori basis for age, smoking, body-mass index, hormone
therapy, and menopausal status. Because CRP levels rise
rapidly with the acute-phase response, we also decided
on an a priori basis to perform separate analyses on the
95.2 percent of the cohort with CRP values < 10 mg/l as
well as on the full cohort (inclusive of those with CRP
levels R 10 mg/l).
For all genotype-phenotype association analyses, we
assumed an additive model of inheritance and initially
conducted univariate linear-regression analyses to test
the null hypothesis that adjusted log CRP levels did not
differ by individual SNP genotypes.12 To conservatively
identify loci that might be associated with CRP levels, we
used an initial criterion of statistical signiﬁcance at a level
of p< 53 108 for single SNP associations in the total sam-
ple. All reported associations were also observed at a < 5 3
108 level of signiﬁcance after adjustment of the test statis-
tic by a genomic-control procedure.12 The genomic-con-
trol inﬂation factor was 1.01, signifying no evidence of
type 1 error inﬂation. As shown in the quantile-quantile
analysis (Figure 1), p values larger than 0.001 conform to
the expected null distribution, again suggesting no inﬂa-
tion of test statistics (red dots). The excess of p values
smaller than 0.001 was solely related to the associations
at the candidate loci; after further adjustment of CRP resid-
uals for variation at the candidate loci, there was no longer
an excess of small p values in genome-wide association
testing (blue dots). Finally, a principal-component analysis
was performed for the exclusion of potential within-Euro-
pean stratiﬁcation in 124,931 SNPs chosen to have pairwise
linkage disequilibrium r2 < 0.04. The ﬁrst ten components
were then used as covariates in the association analysis; be-
cause adjustment by these covariates did not change con-
clusions regarding participants of European ancestry, the
data are presented without further correction for within-
European ancestry.
p values for the association of each individual SNP with
plasma CRP levels according to chromosome number
and position are shown in Figure 2; the top half of Fig-
ure 2 shows data for study participants with CRP levels
< 10 mg/l, whereas the bottom half shows data for the
full cohort.1186 The American Journal of Human Genetics 82, 1185–1192, MayIn the full cohort, 46 SNPs were individually associated
with CRP at a genome-wide level of signiﬁcance (p < 5 3
108). All 46 of these SNPs clustered in one of seven chro-
mosomal regions: nine in chromosome locus 1q31.3,
associated with the leptin-receptor gene (LEPR [MIM
601007]); 20 in chromosome locus 1q23.2, associated
with the CRP gene (MIM 123260); two in chromosome
1q21.3, associated with the interleukin-6 receptor protein
gene (IL6R) (MIM 147880); three in chromosome locus
2p23.3, associated with a glucokinase regulatory protein
gene (GCKR) (MIM 600842); eight in chromosome locus
12q24.31, associated with an hepatic transcription-factor
gene (HNF1A) (MIM 142410) that codes for hepatic nuclear
factor 1-alpha; two in chromosome locus 19q13.32, near
the apolipoprotein E gene (MIM 107741); and two in
a gene-desert region of chromosome 12q23.2. As shown
in Table 1, p values for lead SNPs within the seven loci
ranged from 1.9 3 108 to 6.2 3 1028. Table 1 also shows
the considerable internal consistency in these data for the
separate WGHS-1 and WGHS-2 subpopulations of the
larger cohort. Replication of the HNF1A ﬁnding and repli-
cation of the known CRP and APOE ﬁndings are also
provided in the accompanying manuscript from Reiner
et al. With respect to GCKR, IL6R, and LEPR, the Reiner
data also support replication, albeit at p values of 0.005,
0.04, and 0.05, respectively.
In analyses restricted to those study participants with
CRP levels < 10 mg/l, virtually identical results were
observed for SNPs in the LEPR, CRP, GCKR, HNF1A, and
APOE loci (all p values < 108). However, in this group
with CRP levels generally below concentrations associated
with the acute-phase response, the lead SNPs in the IL6R
Figure 1. Quantile-Quantile Plot of Actual and Expected
p Values for Association with CRP2008
Figure 2. p Values for the Association of Individual SNPs with Plasma CRP Levels According to Chromosome Number and Position
(Top) Data for study participants with CRP levels < 10 mg/l.
(Bottom) Data for the full study cohort. The red horizontal line corresponds to a p value of 108.locus and in the gene-desert region had slightly lower
levels of statistical signiﬁcance (p¼ 1.653 107 and 1.063
107, respectively).
Figure 3 presents data thatmap each SNP according to its
physical location at each of the seven loci, as well a plot of
the p values in relation to the genetic distance from the
lead SNPand the known recombinationhotspots according
to HapMap. Many of the SNPs evaluated tended to group
into easily recognizable linkage blocks, and several SNPs
with genome-wide signiﬁcance fell into blocks that in-
cluded several genes. For example, the two highly signiﬁ-
cant SNPs near the APOE locus are in a block that includes
theAPOC1 [MIM107710] andTOMM40 [MIM608061] loci.
Table 2 presents results of backward-selection models
using the Akaike Information Criterion to seek nonredun-
dant SNPs contributing to CRP level at each of the seven
loci; in this analysis, all potential SNPs with p values of
104 or smaller within 500kB of the locus SNPs with p <
107 were considered in order to avoid inadvertent exclu-
sion of modest effects. This procedure yielded a subset of
nonredundant SNPs accounting for the common geneticThe Amvariance in CRP at each locus after adjustment for clinical
and environmental factors. Also shown in Table 2 are the
crude median levels of CRP (mg/l) for homozygous
minor-allele carriers, heterozygotes, and homozygous
major-allele carriers of each of the nonredundant SNPs
that inﬂuenced CRP levels within each of the seven loci.
In each instance, carriers of the SNP of interest expressed
markedly different ranges of CRP; for example, median
levels of plasma CRP were 1.40, 1.88, and 2.09 mg/l for
homozygous minor allele carriers, heterozygotes, and
homozygous major allele carriers, respectively, for SNP
rs1892534 in the LEPR gene (p ¼ 6.5 3 1021). In aggre-
gate, after adjustment for the clinical and environmental
factors, 10.1 percent of the residual variation in CRP was
explained by the common polymorphism observed in
these seven loci. When examined on a per-locus basis,
the greatest contributor to this residual variation in our
data was attributable to polymorphism in the CRP gene
(3.4 percent). For comparison, 1.6 percent was attributable
to polymorphism in the LEPR gene, 1.5 percent to poly-
morphism in the apolipoprotein E gene, 1.1 percent toerican Journal of Human Genetics 82, 1185–1192, May 2008 1187
Table 1. SNPs, Beta Coefficients, and p Values associated with Plasma CRP Levels in the Women’s Genome Health Study
WGHS-1 (N ¼ 4418) WGHS-2 (N ¼ 1927) WGHS-Combined (N ¼ 6345)
Gene Loci SNP Beta p value Beta p Value Beta p Value
LEPR 1q31.3 rs1892534 0.173 1.53 3 1015 0.166 3.74 3 107 0.170 6.52 3 1021
rs2889195 0.171 5.04 3 1015 0.166 4.51 3 107 0.168 2.78 3 1020
rs2211651 0.170 7.45 3 1015 0.168 3.32 3 107 0.168 3.10 3 1020
rs12753193 0.157 6.91 3 1013 0.151 5.03 3 106 0.154 3.27 3 1017
rs2186245 0.176 5.41 3 1011 0.156 2.39 3 104 0.168 1.27 3 1013
rs12022410 0.126 4.03 3 109 0.137 2.43 3 105 0.128 7.48 3 1013
rs7539471 0.115 5.33 3 107 0.140 5.52 3 105 0.122 1.87 3 1010
rs4291477 0.107 5.95 3 107 0.122 1.80 3 104 0.110 7.65 3 1010
rs4655537 0.112 6.42 3 107 0.110 9.14 3 104 0.110 3.28 3 109
CRP 1q23.2 rs3091244 0.207 1.45 3 1020 0.193 7.63 3 109 0.203 6.16 3 1028
rs1205 0.205 5.47 3 1020 0.184 5.93 3 108 0.199 1.65 3 1026
rs7553007 0.207 2.68 3 1020 0.179 1.35 3 107 0.199 2.16 3 1026
rs2794520 0.202 2.18 3 1019 0.185 4.33 3 108 0.197 4.74 3 1026
rs2027471 0.200 3.00 3 1019 0.164 1.13 3 106 0.190 1.97 3 1024
rs2592887 0.162 4.78 3 1014 0.151 3.65 3 106 0.159 1.04 3 1018
rs1417938 0.146 2.90 3 1010 0.178 4.40 3 107 0.156 9.72 3 1016
rs3116653 0.147 2.23 3 1010 0.176 6.39 3 107 0.156 9.91 3 1016
rs3116636 0.147 2.59 3 1010 0.176 5.69 3 107 0.155 1.06 3 1015
rs3122012 0.145 4.22 3 1010 0.176 6.34 3 107 0.154 1.95 3 1015
rs3116651 0.145 5.27 3 1010 0.181 4.26 3 107 0.155 1.91 3 1015
rs3116656 0.144 5.45 3 1010 0.175 6.97 3 107 0.153 2.78 3 1015
rs1800947 0.300 3.90 3 1012 0.241 2.40 3 104 0.283 5.08 3 1015
rs12093699 0.132 1.60 3 108 0.126 2.95 3 104 0.130 2.15 3 1011
rs12068753 0.286 2.17 3 1010 0.149 3.72 3 102 0.249 6.70 3 1011
rs3093075 0.280 4.82 3 1010 0.160 2.52 3 102 0.248 7.72 3 1011
rs3093059 0.284 2.77 3 1010 0.146 4.06 3 102 0.247 9.28 3 1011
rs11265260 0.289 5.64 3 1010 0.150 3.63 3 102 0.249 1.99 3 1010
rs3093068 0.274 1.45 3 109 0.158 2.80 3 102 0.243 2.34 3 1010
rs12744244 0.127 3.04 3 106 0.121 1.81 3 103 0.123 3.12 3 108
IL6R 1q21.3 rs8192284 0.095 1.09 3 105 0.119 2.81 3 104 0.101 1.93 3 108
rs4129267 0.096 9.33 3 106 0.117 3.54 3 104 0.101 1.97 3 108
GCKR 2p23.3 rs780094 0.142 3.97 3 1011 0.136 3.80 3 105 0.140 6.73 3 1015
rs1260326 0.136 2.18 3 1010 0.139 3.18 3 105 0.16 3.57 3 1014
rs1260333 0.112 4.69 3 107 0.106 1.65 3 103 0.110 2.69 3 109
Unknown 12q23.2 rs10778213 0.109 3.65 3 107 0.128 7.00 3 105 0.115 1.16 3 1010
rs2292996 0.089 2.96 3 105 0.113 4.87 3 104 0.096 5.98 3 108
HNF1A 12q24.31 rs7310409 0.120 4.63 3 108 0.237 1.81 3 1012 0.154 6.75 3 1017
rs735396 0.117 1.70 3 107 0.223 1.12 3 1012 0.147 5.39 3 1015
rs1169300 0.112 1.81 3 106 0.230 1.64 3 1010 0.146 1.15 3 1013
rs2464196 0.108 4.37 3 106 0.231 1.44 3 1010 0.143 3.32 3 1013
rs7953249 0.102 2.67 3 106 0.201 1.42 3 109 0.130 6.98 3 1013
rs2650000 0.093 3.64 3 105 0.198 9.90 3 109 0.123 7.13 3 1011
rs1169302 0.094 1.23 3 105 0.148 6.36 3 106 0.110 9.29 3 1010
rs1169307 0.100 7.19 3 106 0.112 9.14 3 104 0.103 2.90 3 108
APOE 19q13.32 rs769449 0.276 8.57 3 1017 0.227 1.09 3 105 0.261 8.90 3 1021
rs2075650 0.213 4.65 3 1012 0.200 2.37 3 105 0.209 6.80 3 1016
Adjustments made for age, smoking status, body-mass index, hormone-therapy use, and menopausal status.polymorphism in the GCKR gene, 1.1 percent to polymor-
phism in theHNF1A gene, 0.8 percent to polymorphism in
the gene-desert region, and 0.6 percent to polymorphism
in the IL6R gene. We repeated the model selection, using
a more stringent backward-forward procedure with the
Bayes Information Criterion, and observed similar locus-
wide proportion of variance explained, but with a smaller
number of critical SNPs retained in the regression models.
These SNPs are underlined in Table 2.
Despite adjustment of CRP concentration for body-mass
index prior to genetic analysis, we sought further evidence1188 The American Journal of Human Genetics 82, 1185–1192, Mayto exclude the possibility of residual confounding by this
factor. In this regard, none of the lead SNPs reported here
had even a modest level of signiﬁcance for association
with body-mass index (range of p values: 0.02 to 0.70).
We believe these genetic data linking inﬂammation and
CRP to loci known functionally to relate to metabolic
syndrome, insulin resistance, weight homeostasis, and pre-
mature atherothrombosis to be of considerable interest
given epidemiologic data linking CRP concentrations to
early diabetogenesis and atherogenesis. Although recent
work in diabetic and nondiabetic populations has linked2008
Figure 3. Genomic Context for Each of Seven Loci with Genome-wide Association with CRP Levels
(A) LEPR locus; (B) CRP locus; (C) IL6R locus; (D) GCKR locus; (E) gene-desert region on 12q23.2; (F) HNF1A locus; (G) APOE locus.
Upper panel: Genes from RefSeq release 25. Only one isoform is shown when multiple splicing variants are known.
Lower panel: SNPs are plotted according to their physical location with the y axis, indicating p values for association with CRP (red dots).
Also shown is the genetic distance in cM from the lowest p value SNP for each locus (light-gray line), along with the position of
recombination hotspots (light-gray vertical bars). Recombination rates and hotspots are based on HapMap data.32,33The American Journal of Human Genetics 82, 1185–1192, May 2008 1189
Table 2. Nonredundant SNPs in Each of Seven Loci that Contribute to Adjusted CRP Levels in Backward-Selection Models
Median hsCRP Level (mg/l) Locus-wideVariance
Gene SNP Chromosome Position MAF HW A1-A2 A1A1 A1A2 A2A2 Explained (%)
LEPR rs1892534 1 65878531 0.384 0.11 A-G 1.40 1.88 2.09 1.6
rs12753193 1 65942266 0.375 0.11 G-A 1.41 1.88 2.08
rs7539471 1 65957990 0.315 0.25 A-G 2.24 1.91 1.79
rs12409877 1 65716459 0.392 0.16 A-G 1.69 1.82 2.07
rs5010905 1 65971810 0.260 0.03 G-A 2.15 1.97 1.80
CRP rs3091244 1 157951288 0.360 0.94 T/A-G* 2.41 2.03 1.66 3.4
rs1800947 1 157950061 0.065 0.92 G-C 0.73 1.61 1.95
rs3122012 1 157955946 0.302 0.95 G-A 2.25 2.04 1.74
rs3093059 1 157951759 0.059 0.91 G-A 2.05 2.34 1.84
rs4131568 1 157988679 0.334 0.37 A-G 2.11 1.98 1.77
rs3116654 1 157962384 0.126 0.22 G-A 1.22 1.65 1.99
rs863013 1 157466643 0.330 0.60 A-C 1.66 1.82 2.01
IL6R rs4129267 1 152692887 0.398 0.20 A-G 1.65 1.95 1.98 0.6
rs12750774 1 152783100 0.304 0.29 A-G 1.63 1.84 2.01
GCKR rs780094 2 27594740 0.401 0.07 A-G 2.17 1.92 1.74 1.1
rs1260333 2 27602127 0.453 0.74 A-G 2.11 1.86 1.81
rs780106 2 27535101 0.382 0.04 C-A 1.81 1.86 1.98
rs1647266 2 27546988 0.382 0.04 G-A 1.81 1.87 1.98
rs13013484 2 27842324 0.270 0.67 G-A 1.62 1.82 1.98
Unknown rs10778213 12 102019280 0.468 0.71 G-A 1.75 1.85 2.08 0.8
rs4433630 12 102174160 0.487 0.69 A-G 1.80 187 2.05
HNF1A rs7310409 12 119909243 0.388 0.28 A-G 1.66 1.78 2.15 1.1
rs1169300 12 119915607 0.295 0.45 A-G 1.78 1.74 2.07
rs2464196 12 119919809 0.294 0.43 A-G 1.80 1.73 2.07
rs1169302 12 119916684 0.425 0.49 C-A 1.68 1.86 2.09
APOE rs769449 19 50101841 0.115 0.51 A-G 1.38 1.46 2.00 1.5
rs157580 19 50087105 0.392 0.13 G-A 2.05 1.94 1.76
Adjustments made for age, smoking status, body-mass index, hormone-therapy use, and menopausal status.
Also shown are the crude median blood levels of hsCRP observed among homozygous carriers of the minor allele (A1A1), heterozygotes (A1A2), and
homozygous carriers of the major allele (A2A2) for each selected SNP, and the loci-wide variance in CRP is explained.
MAF denotes ‘‘minor-allele frequency.’’
HW indicates significance of deviation from Hardy-Weinberg equilibrium.
Selection criteria and methods to identify lead SNPs described in text.
* Tri-allelic SNP. The two less-common alleles (T/A) were pooled.polymorphism in the GCKR gene to plasma-triglyceride
and glucose levels,13,14 we are not aware of prior data link-
ing polymorphism in this same genetic locus to CRP level.
However, the product of this gene is a regulatory protein
that inhibits glucokinase in liver and pancreatic-islet cells,
and mutations in the GCKR gene can result in defects in
sensitivity of beta cells to glucose as a result of reduced
glucose phosphorylation and limited hepatic storage of
glucose as glycogen. As such, through its regulatory effect
on the GCK protein, the GCKR gene has been considered
a possible susceptibility-gene candidate for one type of
maturity-onset diabetes of the young (MODY-2, MIM
606391).15,16 In this light, it is also of interest that a second
loci described here as a genetic determinant of CRP, hepatic
transcription factor-1 that codes for hepatic nuclear factor
1-alpha, is known to be functionally linked to a different
type of MODY (MODY-3, MIM 606391), a form of non-
insulin-dependent diabetes with an autosomal-dominant
inheritance pattern with a young age of onset (typically
< 25 years of age) and primary defects of insulin secre-
tion.15 Moreover, given that the human CRP promoter is
known to be activated by direct interaction with the1190 The American Journal of Human Genetics 82, 1185–1192, MayHNF-1 protein,17 our ﬁnding in this genome-wide associa-
tion study—that HNF1A polymorphism has a signiﬁcant
impact on CRP levels—would appear to have a strong func-
tional basis.
We also believe our data regarding polymorphism in the
leptin receptor protein to be compelling, not only because
we replicate prior work demonstrating leptin to be an
inﬂammatory modulator via genetic links to CRP18 but
also because these data provide insights linking CRP to
weight homeostasis. In humans, prior work has shown lep-
tin levels to correlate with blood CRP levels and with
vascular risk.19 Further, leptin at physiologic or pharmaco-
logic doses increases plasma CRP, whereas reductions in
leptin during weight loss and exercise are accompanied
by reductions in plasma CRP. Interestingly, Chen et al.
have recently demonstrated that leptin resistance can be
induced through a direct binding of CRP to leptin and
that infusion of human CRP into ob/ob mice blocks the
clinical effects of leptin on satiety and weight reduction;20
this observation hints at a putative positive-feedback role
for CRP in the pathophysiology of obesity. Regulation of
adiposity also yields changes in adipose-derived cytokines2008
such as IL-6, which have previously been shown in this
cohort to correlate positively with CRP levels and to inde-
pendently predict risk of future vascular events and diabe-
tes.21 In this regard, our ﬁnding in the full cohort that
polymorphism in the IL6R gene is an additional determi-
nant of CRP expression is consistent with data linking
IL-6 to hepatic production of CRP and suggesting a role
for IL-6 in both incident diabetes and atherothrombosis.22
Moreover, the association reported here between IL6R and
CRP is also consistent with recent data from the Health
ABC study, in which IL6R was found to be signiﬁcantly
associated with plasma IL-6 levels.23
With regard to SNPs within or near the CRP gene and
APOE locus, our data are consistent with prior work from
candidate-gene studies that have linked CRP concentra-
tion to each of these genetic regions.6–10,24–26 Although
we did not explicitly ascertain the SNPs that determine
the canonical E2, E3, and E4 genotypes in the APOE
region, these are known to associate with risk of myocar-
dial infarction and premature atherothrombosis.27 Addi-
tional evidence links polymorphism in this region to
dysfunction of bacterial lipid-antigen presentation in in-
nate immunity28 and to the development of metabolic
syndrome.29
The data described here suggest that most of the com-
mon genetic polymorphism that contributes to CRP level
is closely related to genic pathways known to have an im-
pact on insulin resistance, weight gain, beta-cell function,
diabetes, and early atherogenesis. This is an intriguing ob-
servation, given that diet, exercise, glucose control, and
statin therapy—the basic interventions for patients at
high vascular risk due to metabolic syndrome—all reduce
CRP levels. Recent work has identiﬁed polymorphisms
within the CRP gene that associate with circulating CRP
levels and with incident vascular events, data that support
a potential causal role for CRP itself.30 Moreover, direct
CRP inhibitors with apparent vascular-protective effects
have recently been described.31 However, it remains con-
troversial as to whether CRP itself is a target for therapy,
and other data (albeit with limited power to deﬁne an
informative null result) have not linked CRP polymor-
phism to incident events. On the basis of the inheritance
patterns observed here, continued investigations into the
potential mechanisms whereby CRP reduction might
impact each of these interrelated disease states appear
warranted.
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